



Patent Application  
Attorney Docket No. PC10861 BTG

I hereby certify that this correspondence is being deposited with the United States Postal Service as first-class mail in an envelope addressed to: Hon. Director - U.S. Patent and Trademark Office, Washington, D.C. 20231 on this 29th day of October 2001.

By

*Kelley D. Surprenant*  
(Signature of person mailing)

Kelley D. Surprenant

(Typed or printed name of person)

RECEIVED  
DEC 07 2001  
TECH CENTER 600/2900

1625

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

IN RE APPLICATION OF: Philip A. Carpino, et al. :

APPLICATION NO.: 09/891,026 : Examiner: To be assigned

FILING DATE: June 25, 2001 : Group Art Unit: 1625

TITLE: Melanocortin Receptor Ligands :

Hon. Director - U.S. Patent and Trademark Office  
Washington, D.C. 20231

Sir:

INFORMATION DISCLOSURE STATEMENT  
PURSUANT TO 37 C.F.R. § 1.97 ET SEQ.

Applicant(s) herein make(s) available to the U.S. Patent and Trademark Office a copy of PTO-FB-A820 which lists the references cited by the applicant(s), copies of which are enclosed.

The Examiner is requested to consider carefully the complete text of these references in connection with the examination of the above-identified application in accord with 37 C.F.R. § 1.104(a). It is believed the Examiner will concur with applicant's belief that the subject matter presently claimed is neither anticipated nor rendered obvious by the foregoing references.

It is requested that the references listed on the attached form PTO-FB-A820 be included in the "References Cited" portion of any patent issuing from this application (M.P.E.P. § 1302.12).

A prompt and favorable response is earnestly solicited.

Date:

*OCTOBER 29, 2001*

Respectfully submitted,

*B. Timothy Creagan*

B. Timothy Creagan  
Attorney for Applicant(s)  
Reg. No. 39,156

Pfizer Inc.  
Patent Department, MS 4159  
Eastern Point Road  
Groton, Connecticut 06340  
(860) 715-4546